Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Bedaquinoline impurity 1 is a chemical impurity associated with Bedaquinoline, a compound used in the treatment of tuberculosis. This impurity can affect the efficacy and safety profile of Bedaquinoline-containing formulations. It is useful for analytical research, particularly in the development and quality control of anti-tuberculosis medications. -
Drug Impurity
Vildagliptin impurity 1 is a synthetic byproduct of Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This impurity serves as a critical reference standard in analytical and quality control applications. Its characterization is essential for ensuring the purity and efficacy of pharmaceutical formulations containing Vildagliptin. Researchers can utilize this compound for method development, validation, and testing related to drug stability and compliance. -
Drug Impurity
Aprepitant impurity 1 is identified as a drug impurity associated with Aprepitant. This compound is primarily utilized for quality control and validation processes in pharmaceutical research. Its characterization is essential for ensuring the purity and effectiveness of Aprepitant formulations in various therapeutic applications. -
Drug Impurity
Diclofenac impurity 7 is a known impurity of the non-steroidal anti-inflammatory drug Diclofenac. It serves as a reference standard for quality control and validation in pharmaceutical research, particularly for the synthesis and analysis of Diclofenac formulations. This compound is crucial for ensuring the purity and safety of drug products containing Diclofenac. -
Drug Impurity
Methyl 2-methoxybenzoate is a chemical compound often identified as a drug impurity. It serves as a useful reference material in analytical chemistry for the identification and quantification of synthetic byproducts in pharmaceutical formulations. Its primary applications include stability studies and quality control assessments in drug production. -
Adamantane impurity
1,3-Dimethyladamantane is a chemical compound associated with the adamantane family. It serves as an impurity in adamantane synthesis, impacting the purity and characteristics of final products. Its presence can influence various biological activities and is relevant for analytical applications in chemical research and pharmaceutical development. -
Drug Impurity
Sitagliptin impurity 4 is a drug impurity associated with the DPP-4 inhibitor Sitagliptin. As a byproduct in the synthesis of Sitagliptin, it serves as an important reference standard for analytical applications. Its characterization is essential for ensuring the quality and safety of pharmaceutical formulations containing Sitagliptin, supporting research in diabetes treatment and drug development. -
Drug Impurity
tert-Butyl (2-hydroxypropyl)carbamate is classified as a drug impurity. Its presence in pharmaceutical formulations can serve as a marker for the assessment of purity and stability in drug development. This compound is utilized in analytical chemistry to ensure the quality and safety of therapeutic agents. -
Drug Impurity
5''-Methyl-apixaban is a structural analogue of apixaban, primarily characterized as a drug impurity. This compound is relevant in analytical chemistry for the development and validation of quality control assays, ensuring the purity of apixaban formulations. Its assessment is vital for understanding the stability and safety profiles of pharmaceutical products containing apixaban. -
Drug Impurity
Aripiprazole impurity 1 is a specific chemical impurity associated with the antipsychotic agent Aripiprazole. Its identification and characterization are essential for quality control and regulatory compliance in pharmaceutical development. This impurity can be utilized in research focused on drug formulation stability, impurity profiling, and pharmacokinetic studies related to Aripiprazole. -
Drug Impurity
2-Bromo-1-(4-hydroxyphenyl)propan-1-one is identified as a drug impurity, characterized by its potential to influence the safety and efficacy profiles of pharmaceutical formulations. This compound may play a role in assessing the stability and consistency of drug products. Its relevance extends to applications in quality control, analytical chemistry, and pharmaceutical research to ensure compliance with regulatory standards. -
Drug Impurity
Edoxaban impurity 7 is a derived impurity of the anticoagulant Edoxaban, primarily identified for quality control purposes in pharmaceutical research. It is crucial for assessing the purity and stability of Edoxaban formulations during development and manufacturing processes. Analytical studies involving Edoxaban impurity 7 aid in the evaluation of drug safety and efficacy by ensuring compliance with regulatory standards in medicinal chemistry. -
Drug Impurity
Pitavastatin impurity 1 is an impurity associated with the cholesterol-lowering agent Pitavastatin. This compound is relevant for assessing the purity and quality of pharmaceutical formulations containing Pitavastatin. It serves as an important tool in drug development and testing to ensure compliance with regulatory standards and to evaluate potential effects on efficacy and safety profiles. -
Drug Impurity
Ibuprofen impurity 8 is a known impurity associated with the non-steroidal anti-inflammatory drug, Ibuprofen. This compound serves as a reference standard for analytical methods in pharmaceutical development and quality control. Its characterization and quantification are essential for ensuring the purity and efficacy of Ibuprofen formulations in compliance with regulatory standards. -
Drug Impurity
Acebutolol impurity 5 is a known impurity associated with the pharmaceutical compound Acebutolol. This reagent can be utilized in the assessment of drug purity and stability, contributing to quality control and regulatory compliance in pharmaceutical development. Its role in analytical chemistry makes it essential for researchers focused on drug formulation and safety. -
Drug Impurity
Duloxetine impurity 11 is a chemical impurity associated with Duloxetine, a serotonin-norepinephrine reuptake inhibitor. This impurity can be relevant for assessing the quality and purity of pharmaceutical formulations containing Duloxetine. Research applications include analytical chemistry, pharmaceutical development, and stability testing to ensure compliance with regulatory standards. -
Drug Impurity
Apster Impurity 51 is a chemical impurity associated with pharmaceutical formulations. It serves as an important reference standard for analytical methods related to drug quality and safety. The compound is utilized in research applications focused on impurity profiling, stability testing, and compliance with regulatory guidelines for drug development. -
Drug Impurity
Sorafenib impurity 2 is a chemical impurity of the multikinase inhibitor Sorafenib. This impurity can be utilized for the qualitative analysis and characterization of Sorafenib formulations in pharmaceutical research. Its presence must be monitored to ensure the purity and efficacy of drug products in development and to assess their safety profiles in biological applications. -
Pyridoxine cyclic ether Impurity
6-Methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol hydrochloride serves as a pyridoxine cyclic ether impurity. This compound is primarily utilized in chemical research focused on the characterization and analysis of pyridoxine derivatives. Its presence may impact the stability and efficacy of related compounds, making it an essential reference standard for quality control and purity assessments in pharmaceutical development. -
Drug Impurity
Sertraline impurity 14 is a chemical impurities derived from the selective serotonin reuptake inhibitor (SSRI) sertraline. This compound serves as a critical reference standard for the quality control and analysis of pharmaceutical formulations containing sertraline. Its characterization is essential for ensuring the purity and compliance of drug products, providing valuable insights into metabolite behavior and stability during research applications. -
Drug Impurity
Aripiprazole impurity 9 is identified as a pharmaceutical impurity of Aripiprazole. It serves as an important reference standard for quality control and analytical studies in drug development. This compound is essential for researchers focused on the identification and quantification of impurities in pharmaceutical formulations, ensuring compliance with regulatory standards. -
Drug Impurity
Apixaban impurity 4 is a known impurity of the anticoagulant Apixaban, primarily utilized for assessing drug purity and quality control during pharmaceutical development. Its presence can influence pharmacological efficacy and safety assessments, making it relevant in analytical chemistry and regulatory compliance studies. This reagent aids in the detailed characterization of Apixaban formulations and contributes to the understanding of potential variations in drug composition. -
Drug Impurity
Bupropion impurity 15, chemically identified as 3-Bromophenyl Ethyl Ketone, serves as a drug impurity associated with the antidepressant Bupropion. This compound is commonly used in the assessment of pharmaceutical quality and purity standards, as well as in the study of drug metabolism and pharmacokinetics. Its analysis is crucial for ensuring the safety and efficacy of Bupropion formulations in therapeutic applications. -
Drug Impurity
Ibrutinib impurity 2 is a chemical impurity associated with the drug Ibrutinib, which targets Bruton's tyrosine kinase (BTK). As a research reagent, it can be utilized in studies investigating the purity and stability of pharmaceutical formulations, as well as in the development of analytic methods for quality control. Its presence in formulations may influence drug efficacy and safety profiles, making it relevant for ongoing pharmaceutical research. -
Drug Impurity
Sitagliptin impurity 6 is a known impurity associated with the antidiabetic medication Sitagliptin. This compound may be utilized in quality control and validation processes for the characterization of Sitagliptin formulations. Its presence and analysis are important for ensuring the safety and efficacy of pharmaceutical products containing Sitagliptin. -
Drug Impurity
Aripiprazole impurity 27 is identified as a drug impurity associated with the antipsychotic agent Aripiprazole. This compound is important for analytical and quality control studies in pharmaceutical research, as it aids in assessing the purity and stability of Aripiprazole formulations. Its characterization is essential for regulatory compliance and ensuring the safety and efficacy of related therapeutic products. -
Drug Impurity
Dacomitinib impurity 3 is a known impurity associated with the tyrosine kinase inhibitor Dacomitinib. This compound can be utilized in analytical studies to evaluate the purity and stability of pharmaceutical formulations containing Dacomitinib. Its characterization is essential for ensuring the quality and compliance of drug products in the development process. -
Drug Impurity
Clopidogrel impurity 3 is a known impurity associated with Clopidogrel, a popular antiplatelet medication. This compound serves as an important analytical reference in the assessment of drug purity and quality control. Its characterization is essential for the evaluation of formulation stability and potential pharmacological effects during research and development. -
Drug Impurity
Ticagrelor impurity 22 is a known impurity associated with Ticagrelor, a potent P2Y12 platelet receptor inhibitor. This compound is utilized in the characterization of drug formulations and is critical for ensuring the quality and safety of pharmaceutical products. Its study is essential for regulatory compliance and may assist in understanding the stability and degradation pathways of Ticagrelor-based therapies. -
Drug Impurity
Omeprazole impurity 13 is a chemical impurity associated with the proton pump inhibitor omeprazole. It is utilized primarily in drug quality control and stability studies to ensure the purity of omeprazole formulations. The characterization of this impurity is crucial for regulatory compliance and assessing the safety and efficacy of pharmaceutical products containing omeprazole. -
Drug Impurity
2-Hydroxy-3-nitrobenzaldehyde is characterized as a drug impurity, primarily affecting the purity profile of pharmaceutical compounds. This compound serves as an important reference standard in analytical chemistry, utilized in the assessment of drug formulations and in quality control processes. Its presence can impact pharmacokinetics and safety evaluations, making it relevant for research focusing on drug development and regulatory compliance. -
Drug Impurity
Vitamin Impurity 2 is a known impurity associated with Vitamin compounds. It serves as a critical reference standard in pharmaceutical research and development to evaluate the purity and quality of Vitamin formulations. Its identification and quantification are essential for ensuring compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Sunitinib impurity 28 is a recognized impurity associated with Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor. It serves as a critical reference standard in the analysis of Sunitinib and is pivotal for assessing drug purity and stability in pharmaceutical formulations. This impurity is essential for quality control and research applications focused on the metabolism and pharmacokinetics of Sunitinib. -
Drug Impurity
Afatinib impurity 34 is a known impurity associated with the drug Afatinib, an irreversible ErbB receptor tyrosine kinase inhibitor. This compound is primarily utilized for quality control and analytical studies in pharmaceutical development to ensure the purity and compliance of Afatinib formulations. Its characterization is essential for understanding the potential impact of impurities on drug efficacy and safety profiles. -
Drug Impurity
Methyl 3-chlorobenzoate is a compound commonly categorized as a drug impurity. It is utilized in chemical research to study the implications of impurities in drug development processes. This reagent serves as a valuable tool for evaluating the stability and efficacy of pharmaceutical formulations. -
Drug Impurity
Rosuvastatin impurity 46, also known as Rosuvastatin ethyl ester, is a chemical impurity associated with the cholesterol-lowering drug Rosuvastatin. It is utilized primarily in drug development and quality control processes to assess the purity of Rosuvastatin formulations. This reagent aids researchers in understanding the metabolic pathways and potential impacts of drug impurities on pharmacokinetics and safety profiles. -
Drug Impurity
Rosuvastatin impurity 10, also known as 5-Oxo rosuvastatin, is a recognized impurity of Rosuvastatin. This compound serves as a reference standard in the assessment and quality control of Rosuvastatin formulations. Its characterization is essential for ensuring drug purity and compliance with regulatory standards in pharmaceutical research and development. -
Drug Impurity
Rivaroxaban impurity 47 is a chemical impurity associated with the anticoagulant Rivaroxaban, which directly targets factor Xa in the coagulation cascade. This compound serves as a crucial reference standard for quality control and stability testing in pharmaceutical research. Its characterization is essential for evaluating the purity of Rivaroxaban formulations during drug development and regulatory assessments. -
Impurity reference
Rabeprazole sulfone is a metabolite of the proton pump inhibitor Rabeprazole, serving as an impurity reference in pharmaceutical research. This compound is essential for quality control and analytical studies that require the assessment of Rabeprazole's purity. Its identification and quantification support the development of reliable therapeutic formulations and ensure compliance with regulatory standards. -
Drug Impurity
trans-4-[Bis(phenylmethyl)amino]cyclohexanecarboxylic acid functions primarily as a drug impurity. It is relevant in pharmaceutical research, particularly in the assessment of drug purity and the investigation of potential contaminants. This compound aids in understanding the implications of impurities in drug formulation and safety profiles. -
Drug Impurity
Dexamethasone impurity 3 is a known impurity of Dexamethasone, a synthetic glucocorticoid. This compound is relevant in pharmaceutical research and quality control, as it is necessary for assessing the purity and stability of Dexamethasone formulations. Understanding the presence and behavior of this impurity can facilitate the development of more effective and consistent glucocorticoid therapies. -
Drug Impurity
Ticagrelor impurity 12 is identified as a chemical impurity associated with Ticagrelor, an antiplatelet medication. This compound is critical for analytical studies focusing on the purification and identification of drug metabolites. Its characterization is essential for ensuring the safety and efficacy of Ticagrelor in pharmaceutical research and quality control processes. -
Drug Impurity
Cinacalcet impurity 6 is a known impurity related to the active pharmaceutical ingredient Cinacalcet, which acts as a calcimimetic agent targeting the calcium-sensing receptor. This compound is utilized primarily in the assessment of drug purity and quality control in pharmaceutical development. Proper identification and quantification of this impurity are essential for ensuring the safety and efficacy of drug formulations containing Cinacalcet. -
Drug Impurity
Ticagrelor impurity 26 is a known impurity associated with the antiplatelet agent Ticagrelor, primarily targeting the P2Y12 receptor. This compound is crucial for the study of drug purity and quality control in pharmaceutical development. It aids researchers in understanding the implications of impurities on drug efficacy and safety, making it an essential tool for analytical and formulation studies in the pharmaceutical industry. -
Drug Impurity
Sildenafil impurity 17 is a defined impurity associated with the synthesis of Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor. This compound is important for assessing the purity of pharmaceutical formulations and plays a critical role in quality control during drug development. Researchers can utilize Sildenafil impurity 17 to ensure compliance with regulatory standards and investigate its impact on the efficacy and safety profiles of Sildenafil-based therapies. -
Drug Impurity
Anastrozole impurity 1 is a known impurity derived from the aromatase inhibitor Anastrozole, primarily targeting estrogen synthesis. This compound is critical for analytical chemistry and quality control in the pharmaceutical industry, serving as a reference standard for the identification and quantification of impurities in formulations containing Anastrozole. Researchers utilize it to ensure the purity and safety of drug products in compliance with regulatory standards. -
Drug Impurity
Ticagrelor impurity 7 is a known impurity associated with the antiplatelet agent Ticagrelor. This compound serves as a reference standard for the analysis and quality control of Ticagrelor in pharmaceutical formulations. Its identification is critical for ensuring the consistency and safety of Ticagrelor-based therapies in drug development and research applications. -
Drug Impurity
Rebamipide impurity 13 is a recognized impurity associated with Rebamipide, a drug primarily used for its gastroprotective properties. This compound serves as a valuable reference standard in the analysis and quality control of pharmaceutical formulations containing Rebamipide. Its presence may influence the pharmacological profile and therapeutic efficacy, making it essential for research applications focused on drug development and safety assessment. -
Drug Impurity
Voriconazole impurity 1 is a recognized impurity of the antifungal agent Voriconazole, which targets fungal cytochromes P450 to inhibit ergosterol synthesis. This compound is utilized in the evaluation of pharmaceutical purity and stability studies, as well as in toxicological assessments. Its presence can impact the safety profile and efficacy of Voriconazole in clinical applications. -
Drug Impurity
Nintedanib Impurity 10 is a chemical impurity associated with Nintedanib, a targeted therapy for various fibrotic diseases. This compound serves as a reference standard for the analytical assessment of Nintedanib formulations, ensuring the quality and consistency of pharmaceutical preparations. Its presence is critical for quality control and regulatory compliance in drug development processes.
